Source comparison
CJC-1295 vs IGF-1 LR3: Which Peptide Is Better?
A 2019 preclinical study published in the Journal of Endocrinology found that CJC-1295 increased mean growth hormone plasma concentrations by 200–1000% above baseline for up to 6 days following a single subcutaneous administration. But the mechanism matters mo
This comparison does not assign a generated winner or score.
- A 2019 preclinical study published in the Journal of Endocrinology found that CJC-1295 increased mean growth hormone plasma concentrations by 200–1000% above baseline for up to 6 days following a single subcutaneous administration. But the mechanism matters more than the numbers. CJC-1295 works by binding to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary, amplifying the body's existing pulse pattern. IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) skips the pituitary entirely, binding directly to IGF-1 receptors in peripheral tissues with three times the half-life of endogenous IGF-1. The first extends what your body already does; the second replaces it.
- Our team has worked with research facilities using both compounds for tissue growth studies, metabolic research, and receptor kinetics analysis. The gap between choosing the right peptide and choosing the wrong one comes down to understanding receptor saturation, feedback inhibition, and whether your protocol requires pulsatile signaling or sustained receptor occupancy.
- What is the core difference between CJC-1295 vs IGF-1 LR3 in research applications?
- CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that extends endogenous GH pulse amplitude and duration by binding to pituitary somatotrophs. IGF-1 LR3 is a modified form of insulin-like growth factor with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. Increasing half-life from 12–15 hours (native IGF-1) to approximately 20–30 hours and reducing binding affinity to IGF-binding proteins by 90%. CJC-1295 amplifies natural GH secretion patterns; IGF-1 LR3 delivers sustained receptor activation independent of pituitary function.
- The featured snippet answers the mechanism question. But it doesn't address the practical research constraint most protocols face: negative feedback. CJC-1295 stimulates upstream signaling, which means elevated GH triggers downstream IGF-1 production and eventual hypothalamic suppression of further GHRH release. IGF-1 LR3 bypasses this feedback loop entirely because it acts at the tissue level. But that comes with receptor desensitisation risk if dosing intervals don't allow for recovery. This article covers the pharmacokinetic distinctions between CJC-1295 and IGF-1 LR3, their receptor binding profiles, appropriate research contexts for each compound, and why protocols combining both require precise timing to avoid receptor downregulation.